You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Johnson and Johnson
McKesson
Boehringer Ingelheim
Medtronic

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

RIVASTIGMINE Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Rivastigmine, and when can generic versions of Rivastigmine launch?

Rivastigmine is a drug marketed by Alvogen, Amneal Pharms, Breckenridge, Mylan Technologies, Zydus Noveltech Inc, Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Chartwell Rx, Dr Reddys Labs Inc, Macleods Pharms Ltd, Orchid Hlthcare, Sun Pharm, and Watson Labs. and is included in fifteen NDAs.

The generic ingredient in RIVASTIGMINE is rivastigmine tartrate. There are thirty-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the rivastigmine tartrate profile page.

US ANDA Litigation and Generic Entry Outlook for Rivastigmine

A generic version of RIVASTIGMINE was approved as rivastigmine tartrate by SUN PHARM on October 22nd, 2007.

  Start Trial

Drug patent expirations by year for RIVASTIGMINE
Drug Prices for RIVASTIGMINE

See drug prices for RIVASTIGMINE

Recent Clinical Trials for RIVASTIGMINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Royal United Hospitals Bath NHS Foundation TrustPhase 3
University of BristolPhase 3
Ain Shams UniversityPhase 1/Phase 2

See all RIVASTIGMINE clinical trials

Pharmacology for RIVASTIGMINE
Medical Subject Heading (MeSH) Categories for RIVASTIGMINE
Paragraph IV (Patent) Challenges for RIVASTIGMINE
Tradename Dosage Ingredient NDA Submissiondate
EXELON FILM, EXTENDED RELEASE;TRANSDERMAL rivastigmine 022083 2013-01-22
EXELON FILM, EXTENDED RELEASE;TRANSDERMAL rivastigmine 022083 2011-04-27

US Patents and Regulatory Information for RIVASTIGMINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Macleods Pharms Ltd RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 203148-002 Aug 22, 2014 AB RX No No   Start Trial   Start Trial   Start Trial
Chartwell Rx RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 207797-001 Sep 28, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Sun Pharm RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 077131-002 Oct 22, 2007 AB RX No No   Start Trial   Start Trial   Start Trial
Orchid Hlthcare RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 090879-002 Jun 10, 2015 AB RX No No   Start Trial   Start Trial   Start Trial
Sun Pharm RIVASTIGMINE TARTRATE rivastigmine tartrate CAPSULE;ORAL 077131-003 Oct 22, 2007 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Johnson and Johnson
McKesson
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.